Intravenous Mepolizumab for Eosinophilic Esophagitis
What is the purpose of this study?
The Cincinnati Center for Eosinophilic Disorders at Cincinnati Children's Hospital Medical Center is currently conducting a randomized, double-blind, parallel group clinical trial of intravenous mepolizumab. This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous mepolizumab in pediatric subjects with eosinophilic esophagitis, Aged 2 to 17 Years.
Who can participate?
- 2- 17 years of age
- Isolated eosinophil esophagitis defined as greater than / equal to 20 eosinophils / HPF
Ages
Conditions
- Eosinophilic Disorders
- Gastroenterology, Hepatology and Nutrition
- Medications
Who should I contact for more information?
If you are a patient who may be interested in enrolling in this research study or you have further questions, please contact us at 513-803-0153.
Date
Ongoing
